Advertisement

Supportive Care in Cancer

, Volume 25, Issue 5, pp 1673–1686 | Cite as

Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis

  • David Beckwée
  • Laurence Leysen
  • Kaipo Meuwis
  • Nele Adriaenssens
Review Article

Abstract

Background

Although aromatase inhibitors have proven to be an effective treatment of hormone receptor-positive breast cancer in postmenopausal women, aromatase inhibitor-induced arthralgia (AIA) is an adverse event associated with low compliance with treatment. The aim of this literature study is to assess the prevalence of AIA and to provide an overview of significant predictors for the development of AIA.

Methods

A systematic review was conducted using PubMed, Cochrane Library and Web of Science. A meta-analysis was performed and heterogeneity has been investigated by moderator analyses. The meta-analysis was repeated with studies that were considered as best evidence, i.e. studies with an above-average score on the STROBE checklist.

Results

Twenty-one studies (13,177 participants) were included. Prevalence rates ranged from 0.200 to 0.737. Meta-analysis resulted in a pooled estimate of 0.459 (95% CI = [0.397–0.520) with a high heterogeneity (I 2 = 98%). Moderator analysis showed no differences regarding heterogeneity. Predictors for the development of AIA included a body mass index of 25–30 kg/m2 (OR = 0.33), taxane-based chemotherapy (OR = 4.08), stage III cancer (OR = 0.32) and a duration of menopause of 5–10 years (OR = 1.10) or >10 years (OR = 0.44–3.29) (An OR <1 indicates a predictor of lower risk of AIA).

Discussion

Despite the established benefits of AI, an important portion of the patients experiences AIA. More research is needed to investigate the efficacy of treatments such as exercise therapy for AIA.

Keywords

Prevalence Breast cancer Arthralgia Aromatase inhibitor 

Notes

Compliance with ethical standards

Funding

No funding was received to conduct this systematic review with meta-analysis.

Supplementary material

520_2017_3613_MOESM1_ESM.docx (25 kb)
ESM 1 (DOCX 25 kb)

References

  1. 1.
    Boyle P, LB; (2008) World Cancer Report 2008 World Health Organization, International agency for research on CancerGoogle Scholar
  2. 2.
    Ferlay J SI, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J CancerGoogle Scholar
  3. 3.
    Stewart B, WC; (2014) World Cancer Report 2014Google Scholar
  4. 4.
    Wildiers H, Stordeur S, Vlayen J, Scholten R, Van de Wetering F, Bourgain C, Carly B, Christiaans M, Coquyt V, Lifrange E, Schobbens J-C, van Goethem M, Villeirs G, van Limbergen E, Neven P (2013) Breast cancer in women: diagnosis, treatment and follow-up. Belgian health care knowledge centerGoogle Scholar
  5. 5.
    Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Lonati V, Barni S (2013) Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Res Treat 140:233–240CrossRefPubMedGoogle Scholar
  6. 6.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton I, Locker GY, Tobias JS, Grp AT (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMedGoogle Scholar
  7. 7.
    Coates AS, Keshaviah A, Thuerlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret J-M, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492CrossRefPubMedGoogle Scholar
  8. 8.
    Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE (2015) Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol 33:265–271CrossRefPubMedGoogle Scholar
  9. 9.
    Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J (2010) Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat 123:9–24CrossRefPubMedGoogle Scholar
  10. 10.
    Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25:3877–3883CrossRefGoogle Scholar
  11. 11.
    Dizdar O, Oezcakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S, Ozisik Y, Altundag K (2009) Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 27:4955–4960CrossRefPubMedGoogle Scholar
  12. 12.
    Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115:3631–3639CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130:681–689CrossRefPubMedGoogle Scholar
  14. 14.
    Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adhere to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431–436CrossRefPubMedGoogle Scholar
  15. 15.
    Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562CrossRefPubMedGoogle Scholar
  16. 16.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kanematsu M, Morimoto M, Honda J, Nagao T, Nakagawa M, Takahashi M, Tangoku A, Sasa M (2011) The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer 11:436CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Elmagarmid A FZ, Hammady H, Ilyas I, Khabsa M, Ouzzani M (2014) Rayyan: a systematic reviews web app for exploring and filtering searches for eligible studies for Cochrane Reviews Evidence-Informed Publich HealthGoogle Scholar
  19. 19.
    Maunsell E GP, Chlebowski RT, Ingle JN, Alés-Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H (2014) Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin OncolGoogle Scholar
  20. 20.
    Kaufman J (2011) Data extraction and assessment form—templateGoogle Scholar
  21. 21.
    von Elm E AD, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2008) The strengthening the reporting of observational studies in epidemiology (STROBE)statement: guidelines for reporting observational studies. J Clin EpidemiolGoogle Scholar
  22. 22.
    Wallace D, Trikalinos, Lau, Trow, Schmid (2012) Closing the gap between methodologists and end-users: R as a computational back-end. Journal of statistical softwareGoogle Scholar
  23. 23.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials Controlled clinical trials 7: 177–188Google Scholar
  24. 24.
    Higgins JPT GS (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011Google Scholar
  25. 25.
    Slavin RE (1995) Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol 48:9–18CrossRefPubMedGoogle Scholar
  26. 26.
    Boonstra A, van Zadelhoff J, Timmer-Bonte A, Ottevanger PB, Beurskens CH, van Laarhoven HW (2013) Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers. Cancer Nurs 36:52–59CrossRefPubMedGoogle Scholar
  27. 27.
    Horimoto Y, Saito M, Kasumi F (2009) Arthralgia in 329 patients taking aromatase inhibitors. Breast Care 4:319–323CrossRefGoogle Scholar
  28. 28.
    Menas P, Merkel D, Hui W, Lawton J, Harper A, Carro G (2012) Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. J Oncol Pharm Pract 18:387–393CrossRefPubMedGoogle Scholar
  29. 29.
    Moxley G (2010) Rheumatic disorders and functional disability with aromatase inhibitor therapy. Clinical Breast Cancer 10:144–147CrossRefPubMedGoogle Scholar
  30. 30.
    Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper E-M, Sperner-Unterweger B, Holzner B (2011) Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128:553–561CrossRefPubMedGoogle Scholar
  31. 31.
    Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clinical breast cancer 7:775–778CrossRefPubMedGoogle Scholar
  32. 32.
    Scarpa R, Atteno M, Peluso R, Costa L, Padula S, Di Minno MND, Caso F, Iervolino S, Vitiello M, Del Puente A (2011) Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer. Jcr-Journal of Clinical Rheumatology 17:169–172CrossRefPubMedGoogle Scholar
  33. 33.
    Thomas R, Williams M, Marshall C, Walker L (2008) Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women. Br J Cancer 98:1494–1499CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Yagata H, Ohtsu H, Komoike Y, Saji S, Takei H, Nakamura T, Ohashi Y, Iwase T, Shimozuma K (2015) Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole Support Care CancerGoogle Scholar
  35. 35.
    Egawa C, Hirokaga K, Takao S, Yamagami K, Miyashita M, Baba M, Ichii S, Konishi M, Kikawa Y, Minohata J, Okuno T, Miyauchi K, Wakita K, Suwa H, Hashimoto T, Nishino M, Matsumoto T, Hidaka T, Konishi Y, Sakoda Y, Miya A, Mitsunobu M, Nishikawa H, Kono S, Kokufu I, Sakita I, Kitatsuji K, Oh K, Miyoshi Y (2015) Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes International journal of clinical oncologyGoogle Scholar
  36. 36.
    Hadji P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P, Koenig K, Kreienberg R, Rief W, Wallwiener D, Zaun S, Harbeck N (2014) COMPliance and arthralgia in clinical therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol 25:372–377CrossRefPubMedGoogle Scholar
  37. 37.
    Helzlsouer KJ, Gallicchio L, MacDonald R, Wood B, Rushovich E (2012) A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms. Breast Cancer Res Treat 131:277–285CrossRefPubMedGoogle Scholar
  38. 38.
    Laroche F, Coste J, Medkour T, Cottu PH, Pierga J-Y, Lotz J-P, Beerblock K, Tournigand C, Decleves X, de Cremoux P, Bouhassira D, Perrott S (2014) Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. Journal of Pain 15:293–303CrossRefPubMedGoogle Scholar
  39. 39.
    Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. The Lancet Oncology 9:866–872CrossRefPubMedGoogle Scholar
  40. 40.
    Shi Q, Giordano SH, Lu H, Saleeba AK, Malveaux D, Cleeland CS (2013) Anastrozole-associated joint pain and other symptoms in patients with breast. cancer J Pain 14:290–296CrossRefPubMedGoogle Scholar
  41. 41.
    Laroche M, Borg S, Lassoued S, De Lafontan B, Roche H (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. J Rheumatol 34:2259–2263PubMedGoogle Scholar
  42. 42.
    Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L, Do HT, Mandl LA (2012) Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res (Hoboken) 64:1910–1918CrossRefGoogle Scholar
  43. 43.
    Niravath P (2013) Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 24:1443–1449CrossRefPubMedGoogle Scholar
  44. 44.
    Magliano (2010) Menopausal arthralgia: fact or fiction. Maturitas 67Google Scholar
  45. 45.
    Watt (2016 ) Hand osteoarthritis, menopause and menopausal hormone therapy. Maturitas 83Google Scholar
  46. 46.
    Juni P, Holenstein F, Sterne J, Bartlett C, Egger M (2002) Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 31:115–123CrossRefPubMedGoogle Scholar
  47. 47.
    Lefebvre C, Manheimer E, Glanville J (2011) Chapter 6: searching for studies. In: Higgins JPT, S G (eds) Cochrane handbook for systematic reviews of interventions version 510 (updated March 2011)Google Scholar
  48. 48.
    Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13:205CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Nielsen RH, Christiansen C, Stolina M, Karsdal MA (2008) Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin Exp Immunol 152:21–27CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Zhang Y, McAlindon TE, Hannan MT, Chaisson CE, Klein R, Wilson PW, Felson DT (1998) Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham study. Arthritis Rheum 41:1867–1873CrossRefPubMedGoogle Scholar
  51. 51.
    Hart DJ, Doyle DV, Spector TD (1999) Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford study. Arthritis Rheum 42:17–24CrossRefPubMedGoogle Scholar
  52. 52.
    Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52:2594–2598CrossRefPubMedGoogle Scholar
  53. 53.
    Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Van Limbergen E, Weltens C, Van den Bogaert W, De Smet L, Vergote I, Christiaens MR, Neven P (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104:87–91CrossRefPubMedGoogle Scholar
  54. 54.
    Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC (2008) Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 180:630–636CrossRefPubMedGoogle Scholar
  55. 55.
    Vural P, Akgul C, Canbaz M (2006) Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res 54:298–302CrossRefPubMedGoogle Scholar
  56. 56.
    Yang GS, Kim HJ, Griffith KA, Zhu S, Dorsey SG, Renn CL (2016) Interventions for the treatment of aromatase inhibitor-associated arthralgia in breast cancer survivors: a systematic review and meta-analysis Cancer NursGoogle Scholar
  57. 57.
    DeNysschen CA, Burton H, Ademuyiwa F, Levine E, Tetewsky S, O’connor T (2014) Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study. European journal of cancer care 23:493–501CrossRefPubMedGoogle Scholar
  58. 58.
    Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J (2015) Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33:1104–1111CrossRefPubMedGoogle Scholar
  59. 59.
    Sahin S, Karatas F, Sever AR, Altundag K (2016) Current management of aromatase inhibitor-induced arthralgia. J buon 21:17–20PubMedGoogle Scholar
  60. 60.
    Nijs J, Torres-Cueco R, van Wilgen CP, Girbes EL, Struyf F, Roussel N, van Oosterwijck J, Daenen L, Kuppens K, Vanwerweeen L, Hermans L, Beckwee D, Voogt L, Clark J, Moloney N, Meeus M (2014) Applying modern pain neuroscience in clinical practice: criteria for the classification of central sensitization pain. Pain physician 17:447–457PubMedGoogle Scholar
  61. 61.
    Nijs J, Leysen L, Adriaenssens N, Aguilar Ferrandiz ME, Devoogdt N, Tassenoy A, Ickmans K, Goubert D, van Wilgen CP, Wijma AJ, Kuppens K, Hoelen W, Hoelen A, Moloney N, Meeus M (2016) Pain following cancer treatment: guidelines for the clinical classification of predominant neuropathic, nociceptive and central sensitization pain. Acta oncologica (Stockholm, Sweden) 55:659–663CrossRefGoogle Scholar
  62. 62.
    Schiavon G, SI; (2014) Status of adjuvant endocrine therapy for breast cancer Breast Cancer ResearchGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Rehabilitation Sciences Research DepartmentVrije Universiteit BrusselBrusselsBelgium
  2. 2.Frailty in Ageing Research DepartmentVrije Universiteit BrusselBrusselsBelgium
  3. 3.Pain in Motion Research GroupBrusselsBelgium

Personalised recommendations